Non-Therapeutic Biomolecules Market Report 2026

The non-therapeutic biomolecules market size has grown rapidly in recent years. It will grow from $33.92 billion in 2025 to $37.59 billion in 2026 at a compound annual growth rate (CAGR) of 10.8%. The growth in the historic period can be attributed to rising demand for research biomolecules, increasing adoption in in vitro diagnostics, growth in pharmaceutical research, advancements in recombinant protein technology, increasing collaborations between biotech firms.

The non-therapeutic biomolecules market size is expected to see rapid growth in the next few years. It will grow to $56.43 billion in 2030 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to expansion in synthetic biomolecule applications, growing investment in precision medicine, increasing use in agricultural biotechnology, rising focus on sustainable and scalable biomolecule production, innovations in automated biomolecule synthesis platforms. Major trends in the forecast period include advanced protein engineering, high-throughput screening technologies, sustainable biomolecule production, cell-free biomolecule synthesis, customizable biomolecule platforms.

The rapidly growing number of research studies and laboratory tests is expected to drive the expansion of the non-therapeutic biomolecules market in the coming years. Laboratory testing involves analyzing samples of blood, urine, or other substances from the body to detect and monitor diseases and to develop treatment plans. Research, on the other hand, focuses on creating new knowledge or creatively applying existing knowledge to generate new concepts, theories, and understandings. In laboratory testing, non-therapeutic biomolecules are used to measure the presence or concentration of biomarker molecules, which indicate the presence of disease and enhance the sensitivity and specificity of tests. For example, in July 2024, the National Health Service (NHS), a UK-based healthcare provider, reported that diagnostic activity surpassed pre-pandemic levels in 2023, with a 21% increase in tests performed in May 2024 compared to the previous year. As a result, the increasing number of research and laboratory tests is fueling the growth of the non-therapeutic biomolecules market.

Leading companies in the non-therapeutic biomolecules market are focusing on developing new cell separation technologies to increase throughput and optimize processes, gaining a competitive edge. These innovative research-only kits are designed to address biological and laboratory workflow challenges. For instance, in May 2023, AcouSort AB, a Sweden-based biotechnology company, launched the AcouTrap 3 system. This system integrates the unique features of acoustofluidics, combining sound waves with microfluidics, to offer a streamlined solution for cell and extracellular vesicle isolation in a single workflow. The AcouTrap 3 system uses gentle acoustic trapping technology, enabling scientists to process more samples with higher cell viability and minimal loss compared to traditional column- or bead-based methods, thus improving productivity and optimizing laboratory operations.

In December 2023, Danaher Corporation, a U.S.-based life sciences and diagnostics conglomerate providing laboratory instruments, reagents, and consumables, acquired Abcam plc for an undisclosed amount. Through this acquisition, Danaher aims to expand its non-therapeutic biomolecule portfolio and strengthen its research-reagent business by integrating Abcam’s antibodies, proteins, and immunoassay products into its global distribution and solutions platform. Abcam plc, a UK-based provider of research-use antibodies, proteins, immunoassays, and other reagent tools, is widely used in drug discovery, diagnostics, and academic research.

Major companies operating in the non-therapeutic biomolecules market are Amgen Inc., Genentech Inc., Merck KGaA, Lonza Group AG, Bio-Rad Laboratories Inc., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Charles River Laboratories International Inc., GE Healthcare Life Sciences, Fujifilm Diosynth Biotechnologies, Evonik Industries AG, Seikagaku Corporation, Takeda Pharmaceutical Company Limited, MilliporeSigma, Covance Inc., Sartorius AG, Sanofi S.A., CordenPharma International, Bayer AG, WuXi AppTec, Ginkgo Bioworks, Eppendorf AG, Bio-Techne Corporation, Vectalys, Avid Bioservices Inc.

Asia-Pacific was the largest region in the non-therapeutic biomolecules market share in 2025. The regions covered in the non-therapeutic biomolecules market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the non-therapeutic biomolecules market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the non-therapeutic biomolecules market by increasing import costs of laboratory reagents, enzymes, and specialized biomolecule production equipment. This has affected research and pharma segments significantly, especially in Asia-Pacific and North America where imports are high. Industrial enzymes, recombinant proteins, and plasmids are among the most affected segments. Despite challenges, tariffs have encouraged local manufacturing and investment in domestic biomolecule production capabilities, potentially reducing future supply chain risks.

The non-therapeutic biomolecules market research report is one of a series of new reports that provides non-therapeutic biomolecules market statistics, including non-therapeutic biomolecules industry global market size, regional shares, competitors with a non-therapeutic biomolecules market share, detailed non-therapeutic biomolecules market segments, market trends and opportunities, and any further data you may need to thrive in the non-therapeutic biomolecules industry. This non-therapeutic biomolecules market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Non-therapeutic biomolecules refer to organic compounds produced by cells and living organisms. These compounds vary in shape and size and perform a wide range of functions within the body.

The main types of traditional pharmaceutical non-therapeutic biomolecules include enzymes, recombinant proteins, plasmids, peptides, oligonucleotides, and monoclonal antibodies. Enzymes are globular conjugated proteins that accelerate biological reactions by lowering the activation energy, thereby increasing the reaction rate. These biomolecules are utilized by various end users, including research, pharmaceuticals, and in vitro diagnostics (IVD).

The non-therapeutic biomolecule market consists of sales of monosaccharides, disaccharides, polysaccharides, heteropolysaccharides, structural proteins, hormones, respiratory pigments, storage proteins, toxins, deoxyribonucleic acids (DNA), ribonucleic acids (RNA), fatty acids, phospholipids, steroids, eicosanoids, and glycolipids. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.